High flow nasal oxygen therapy by Pickard, K & Harris, S
What you need to know about: High flow nasal oxygen 
therapy 
Main introduction 
Adequate oxygenation is essential in many disorders, and this article will discuss the 
physiology, practicalities and indications of high flow nasal oxygen (HFNO) as a 
novel means of effective oxygen delivery in adults. 
What is HFNO? 
Several options exist to deliver supplemental oxygen to patients, and each will 
provide a varying fraction of inspired oxygen (FiO2). The first distinction to make is 
between fixed and variable performance devices. In fixed performance devices FiO2 
remains constant regardless of inspiratory flow rates; an example being the Venturi 
mask system. Variable performance devices deliver a variable FiO2 depending on the 
patient’s inspiratory flow rate, with examples including nasal cannulae and simple 
face masks. Increasing flow rates will deliver increasing FiO2 up to the limitations of 
the device and patient comfort, with much variation depending on the patient’s 
respiratory pattern. Table 1 summarises the devices available. 
Low-flow nasal oxygen via nasal cannulae typically deliver an FiO2 of 25 to 40% but 
flow rates greater than 4 L/min may cause patient discomfort. This method of 
oxygen delivery is appropriate for patients with a low oxygen requirement and is 
generally well tolerated, as well as being easy to set up and administer at low cost. If 
the oxygen demands of a patient exceed 40% then ward patients will often be 
placed on a simple face mask, with a flow rate of 5 to 15 L/min. Further 
deterioration despite increasing FiO2 may warrant referral to the intensive care unit 
(ICU) for close monitoring and timely intubation and mechanical ventilation in the 
last resort. 
High-flow nasal oxygen (HFNO) therapy uses wide bore, soft nasal cannula devices 
to deliver heated and humidified oxygen at up to 60 L/min, exceeding the patient’s 
peak inspiratory flow rate and thereby acting as a fixed performance device 
(Nishimura, 2016). In terms of equipment required, most HFNO circuits consist of a 
flow meter and oxygen/air blender with heated humidifier and nasal prongs. 
Additional equipment includes a humidification circuit and bacterial filter. Clinical 
variables which require careful monitoring include continuous oxygen saturations 
(SpO2) and arterial blood gas analysis. Within hospitals in the UK, HFNO is often 
colloquially referred to as ‘Optiflow™’ which is a brand of Fisher and Paykel 
Healthcare Limited (Panmure, Auckland, New Zealand). Other brands available 
include Armstrong Medical Ltd and Vapotherm™ (Solus Medical Ltd). Figure 1 
shows the equipment set up of HFNO. 
There are no clear guidelines in terms of measuring treatment response to HFNO, 
however it is important to consider certain measures which indicate treatment 
failure and warrant urgent clinical review to consider invasive ventilation. Sztrymf 
et al (2011) suggest that an improvement within one hour of the ratio of partial 
pressures of arterial O2 (PaO2) to FiO2 (Pa02:FiO2 or simply P:F ratio) or PaO2 alone 
is a predictor of success. Conversely, absence of improvement in respiratory rate, 
work of breathing and PaO2 were early indicators of failure. More simply, a patient 
may simply report a decrease in dyspnoea. Once established on HFNO, and 
assuming the underlying condition improves, consideration can be made to wean 
flow rate before stepping down to conventional oxygen therapy.  
Physiology 
The use of high flow nasal oxygen is now common in ICU patients with acute 
hypoxic respiratory failure and in the immediate period following extubation. 
However the physiological effects of HFNO are still not widely established. Park et al 
(2009) recorded higher nasopharyngeal pressures with HFNO compared to face 
mask; most evident when the patient had their mouth closed (mean 2.7 cm H20). 
This supports other studies which have asserted a low level of positive pressure 
generated in the upper airways.  This increase in positive end-expiratory pressure 
(PEEP) will prevent alveolar collapse thereby improving ventilation-perfusion 
matching and PaO2 (Chikhani et al 2016). 
Mauri et al (2017) investigated the effects of HFNO on several physiological 
parameters. They used oesophageal pressure swings to show a significant reduction 
in inspiratory effort and work of breathing, with improvement in oxygenation. This 
study was also able to estimate changes in lung volume and ventilation, and found 
that HFNO increased end-expiratory lung volumes and improved lung compliance 
compared to simple face mask.  
Improvement in alveolar ventilation could also be driven by a reduction in re-
breathing of expired air. Möller et al (2017) showed that HFNO led to dose-
dependent reduction in re-breathing and subsequent reduction in physiological 
dead space. These findings may explain the decrease in PaCO2 demonstrated by 
Pilcher et al (2017) in patients with exacerbations of COPD when comparing HFNO 
to nasal prongs. However the clinical use of HFNO in COPD remains uncertain. 
It is likely that high flow nasal oxygen therapy exerts many physiological effects 
including an increase in PEEP, reduction in dead space and improved lung 
compliance. Importantly, many studies have found that HFNO is much better 
tolerated by patients compared to non-invasive ventilation, which may improve 
compliance. Although more scientific work is needed to characterise the exact 
physiological effects of HFNO, it appears that it is more than a fixed performance 
oxygen device. 
Indications 
Clinical trials looking at HFNO have mainly focussed on its use in acute hypoxic 
respiratory failure (AHRF) and in those patients extubated following invasive 
ventilation. 
Acute hypoxic respiratory failure 
Respiratory failure is a common reason for referral of patients to higher levels of 
care. There is established evidence supporting non-invasive ventilation (NIV) in 
patients with hypercapnic (or type 2) respiratory failure with underlying chronic 
airways disease. Continuous positive airway pressure therapy (CPAP) is established 
as a treatment for pulmonary oedema secondary to heart failure. The use of NIV or 
CPAP in non-hypercapnic acute respiratory failure (type 1 respiratory failure), 
where heart failure is not a cause, is less well understood and has not been proven 
to be beneficial. For example, Carillo et al (2012) demonstrated an association 
between delayed intubation and increased mortality in patients with AHRF without 
underlying cardiac or respiratory disease who were treated with NIV/CPAP. 
For many patients an optimum strategy for managing hypoxia and an increased 
work of breathing has not been defined. Consider a patient with community 
acquired pneumonia (CAP). There is likely harm from delayed invasive ventilation, if 
this is indeed inevitable, but there is also harm from invasive ventilation and the 
associated paraphernalia of critical care. Non-invasive strategies and a period of 
watchful waiting may minimise harm by reducing physiological strain while waiting, 
and avoiding premature invasive ventilation for those whose underlying condition 
will improve with sufficient rapidity. The next section will look at the evidence base 
behind this strategy, and explore whether HFNO reduces intubation rates and 
improves mortality. 
Frat et al (2015) performed a multi-centre, randomised open-label trial including 
patients with AHRF without hypercapnia in intensive care units. They assigned 
patients to standard oxygen therapy, HFNO or NIV for at least two calendar days. 
Results demonstrated a significant reduction in ICU and 90-day mortality in patients 
who received HFNO compared to standard oxygen therapy and non-invasive 
ventilation. The study failed to demonstrate a statistically significant difference in 
intubation rates between the three groups, except for patients with a P:F ratio of 
<200mmHg (suggestive of severe respiratory failure) where HFNO was favourable. 
The authors postulate that the significant reduction in mortality may be attributable 
to fewer intubations in patients with severe respiratory failure, and call for a larger 
study to investigate this sub-group.  
More recently, Monro-Somerville et al (2017) performed a systematic review and 
meta-analysis. The meta-analysis included 9 trials with a total of 2,507 patients. The 
authors found no significant difference in intubation rates or mortality with HFNO. 
Qualititive analysis showed that HFNO was however well tolerated and improved 
dyspnoea and comfort scores. Lemiale et al (2017) then looked specifically at 
immunocompromised patients with acute hypoxic respiratory failure, and again 
found no statistically significant difference in intubation rates and overall mortality. 
Interestingly a prospective, randomised trial of early, intermittent NIV (Hilbert et al 
2001) in selected immunosuppressed patients did demonstrate a significant 
reduction in intubation rates and mortality, however both studies agree that a 
subsequent randomised study of greater size is required. 
The evidence base is therefore inconclusive and it is very difficult to say confidently 
that HFNO reduces intubation rates and mortality in patients with AHRF. There is 
certainly a trend in these studies towards favourable outcomes in patients with 
HFNO, which fall short of statistical significance. The studies agree that HFNO is at 
least equivalent to other treatments and is better tolerated by patients with 
improvement in subjective work of breathing and comfort. Despite the paucity of 
firm evidence, the use of HFNO is becoming more and more common in the 
intensive care setting and there is much anecdotal evidence of clinical utility. 
Pre-intubation 
Pre-oxygenation strategies (more precisely, de-nitrogenation of the lung 
volume) are used in patients undergoing intubation to increase the time between 
the onset of apnoea at the induction of anaesthesia and arterial desaturation as 
oxygen stored in the open lung volume is consumed, without replenishment by 
normal respiration. Again, in theory, HFNO should act as no more than a fixed 
performance oxygen delivery system during pre-oxygenation. There is evidence of 
its efficacy (Jaber et al, 2016) but more interestingly Patel and Nouraei (2014) 
demonstrated efficacy against desaturation that extended well beyond what would 
be expected as just an oxygen delivery system. In their study, involving the use of a 
simplified HFNO device on patients with difficult airways (THRIVE) before and 
following induction of anaesthesia and neuromuscular blockade, no patient 
desaturated below 90% despite an average apnoea time of 17 minutes. This 
extended ‘apnoeic window’ provided a remarkable margin of safety, and the authors 
conclude that HFNO could be a useful adjunct to anaesthetists during difficult 
intubations. 
Post-extubation 
As discussed previously, HFNO can in theory deliver higher concentrations of 
oxygen compared to conventional oxygen therapy, with improved patient comfort 
and tolerance compared to NIV. The physiological effects may also improve 
secretion management, and so would be an ideal therapy to reduce reintubation 
rates following extubation. Non-inferiority of HFNO compared to NIV has been 
demonstrated previously (Hernandez et al, 2016) and now several studies have 
supported the assertion that HFNO used post-extubation on ICU in fact significantly 
reduces re-intubation rates. Jones and Zappetti (2016) showed a reduction in all-
cause re-intubation with HFNO and an associated reduction in post-extubation 
respiratory failure. 
Contraindications 
Contraindications to HFNO are similar to non-invasive ventilation (Nishimura, 
2016). HFNO is not suitable for unconscious patients (GCS < 8) with absent upper 
airway reflexes who are at high-risk of gastric aspiration and therefore require a 
cuffed oral endo-tracheal tube. HFNO is an option in difficult airways due to partial 
airway obstruction, however will not be effective in complete upper airway 
obstruction. It should also be avoided in those with epistaxis and basal skull 
fractures. As with any method of oxygen supplementation, HFNO should be used 
with caution, or at least under close observation, in patients with hypercapnic 
respiratory failure where decreased respiratory drive or worsening V:Q mismatch 
may lead to further increases in arterial PaCO2. 
More research is needed into the use of HFNO earlier in the care of patients with 
hypoxic respiratory failure to prevent admission to ICU altogether, and whether this 
would improve outcomes such as intubation rate. The appropriateness of the 
delivery of HFNO in a ward-setting without invasive monitoring is debatable, due to 
high-risk of deterioration and subsequent intubation and so use should ideally be 
limited to high-dependency settings or specialist respiratory wards. HFNO could 
also be an option on medical wards to improve work of breathing in patients 
unsuitable for ICU admission or those being treated with palliative intent. 
Conclusion 
HFNO has been rapidly adopted both within and beyond the ICU for patients at risk 
of respiratory deterioration. It is well tolerated by patients and allows them to talk, 
and (with care) eat and drink. HFNO offers many benefits over conventional oxygen 
therapy including the delivery of higher oxygen concentration and provision of low 
levels of positive airway pressure. It would appear that HFNO exerts significant 
physiological benefits by directly reducing the work of breathing and reducing 
respiratory rate thereby improving patient comfort. There is a good evidence base 
for the use of HFNO in theatres and ICU as an adjunct to both intubation and 
extubation. Further studies are needed to establish which groups of patients would 





• High flow nasal oxygen delivers up to 60 L/min of humidified oxygen through a 
nasal cannula 
• HFNO appears to provide some positive pressure ventilation and improve 
physiological measures of work of breathing 
• HFNO is often better tolerated than NIV or CPAP delivered by face mask 
• HFNO should be delivered in a safe clinical environment with close observation 
and equipment available for emergency intubation if indicated 
• There is no firm evidence of a reduction in intubation rates with HFNO, 
however some evidence of a reduction in mortality 
• There appears to be good evidence for the use of HFNO both before intubation 




• High flow nasal oxygen 
• Acute hypoxic respiratory failure 
• Preoxygenation 
• Post-extubation 
• Positive pressure ventilation 
 
Table and figures 
 
Delivery device Flow rates FiO2 
Nasal cannula 1 – 4 L/min 24 – 
35% 
Face mask >5 L/min 40 – 
60% 




15 L/min >60% 




Table 1: Comparison of oxygen delivery devices. FiO2 (fraction of inspired oxygen). 
L/min (litres per minute). HFNO (high flow nasal oxygen). 
 
 
Figure 1: The OptiflowTM system of high flow nasal oxygen. Provided by Fisher & 
Paykel Healthcare Limited. 
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